Macrogenics Inc (NAS:MGNX)
$ 4.47 -0.21 (-4.49%) Market Cap: 279.97 Mil Enterprise Value: 129.75 Mil PE Ratio: 0 PB Ratio: 2.63 GF Score: 62/100

MacroGenics Inc at Barclays Global Healthcare Conference Transcript

Mar 11, 2020 / 02:45PM GMT
Release Date Price: $6.49 (-10.36%)
Peter Richard Lawson
Barclays Bank PLC, Research Division - Research Analyst

Hi. Welcome to Barclays Global Healthcare Conference. My name is Peter Lawson. I'm one of the biotech analysts at Barclays. It's my great pleasure to introduce MacroGenics. With us today, we have Scott Koenig, CEO of MacroGenics. Scott, welcome.

And before we get into the Q&A, perhaps you could give us a high level introduction to the pipeline, therapeutic focus, technology focus and cash runway. Thank you.

Scott Koenig
MacroGenics, Inc. - CEO, President & Director

Sure. Thank you, Peter, for the invitation today. So MacroGenics is a company focused on immune-based therapeutics for the treatment of cancer. We have developed proprietary technologies around the Fc domain of an antibody to enhance its activity to destroy tumors as well as a bispecific technology, which we call DART. Currently, we have 7 molecules in clinical development from Phase I to Phase III. I know we'll be talking about today, our lead asset that is under FDA review, following the BLA submission

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot